Operations, not just discovery
Agentic AI could support 75-85% of operations workflows, cutting task time 25-35% across supply chain, procurement, manufacturing, CMC and quality.
In pharma the technology is rarely the hard part — proving it to a regulator is. A GxP-validated agent needs documented intended use, evidence of testing, change control and periodic review. This specialisation teaches you to build for that from the first commit, not to retrofit it before an audit.
The life sciences value chain is long, gated and expensive to get wrong. Part 1 maps it from discovery to pharmacovigilance, names who owns each gate, and sets out what the strategy houses see shifting.
Six stages from molecule to market surveillance. Select one.
Target identification, screening, lead optimisation and preclinical work.
Protocol design, site selection, recruitment, monitoring and data management.
Process development, tech transfer, batch manufacture and release.
Quality management, CAPA, audits, inspections and validation.
Dossier authoring, health-authority queries, labelling and lifecycle maintenance.
Medical affairs, field engagement, market access and pharmacovigilance.
In pharma, the person who can stop your deployment is usually Quality. Select one to light the stages they own.
The 2026 read on where AI value lands in life sciences.
Agentic AI could support 75-85% of operations workflows, cutting task time 25-35% across supply chain, procurement, manufacturing, CMC and quality.
R&D productivity improves when stage gates become continuous learning loops — which requires data infrastructure most organisations have not built.
Gen AI could unlock $60-110bn annually for pharma and medical products, distributed from discovery through commercial engagement rather than concentrated in one place.
BCG’s 2026 read is that biopharma’s innovation engine is performing while pricing, patent and cost pressure force operating-model change.
Joint guiding principles in early 2026 emphasise intended use, context of use, reliability, transparency, human oversight and GxP adherence.
Updated guidance reinforces risk-based planning, data strategy and continuous monitoring for AI components inside GxP systems.
Consulted when this program was written, in July 2026. Each entry names the claim on this page that it backs, so the pairing stays checkable if the copy is later edited.
A GxP architecture is one where every output can be traced to a validated process. That single requirement drives almost every design decision you will make here.
Six families, split sharply between GxP and non-GxP — know which side you are on.
EDC, CTMS and eTMF — regulated, auditable, and slow to change.
Medidata, Veeva Vault, CDISC SDTMMES, LIMS, batch records, deviations and CAPA.
MES, LIMS, QMSDossiers, labelling, health-authority correspondence and submissions.
eCTD, Veeva RIMPublications, patents, conference abstracts and internal reports.
PubMed, internal repositoriesAdverse event cases, signals and periodic safety reports.
Argus, safety databaseField activity, MLR-approved claims, payer and HCP data.
Veeva CRM, claims libraryIn a regulated environment the vocabulary is part of the submission. Terms that drift between study, dossier and label become findings, so the semantic layer here is a compliance artefact as much as an engineering one.
Six subject areas, each with the entities it holds, its critical data elements and the function accountable for it.
The molecule, its formulations and the products marketed from it.
Clinical studies, their design, sites and the subjects enrolled.
What was observed and measured, standardised for submission.
How it is made, tested and released, and what went wrong.
Submissions, health-authority interactions and approvals by market.
Adverse event cases, signals and periodic reporting.
The entities and the typed relationships between them — what the agent traverses instead of guessing joins. Select any entity.
The active molecule.
A formulated, presented medicine.
A clinical investigation of a product.
The design document governing a study.
An investigational location enrolling subjects.
An enrolled participant.
An untoward occurrence in a subject.
A pre-specified measure of study outcome.
A discrete quantity manufactured to one specification.
A departure from an approved process.
The corrective and preventive action from an investigation.
A dossier filed with a health authority.
The classification hierarchies that make records comparable across systems.
Cardiac disorders → Cardiac arrhythmias → Atrial fibrillation
Module 3 → 3.2.P Drug product → Specification
Process → Major → Out-of-specification result
The definitions an agent must use rather than invent. Most wrong answers in this industry are a term used loosely.
The layers a deployment needs, what each one holds, and what the engineer owns there.
Seven layers, with validation evidence generated as a by-product of the build.
EDC, LIMS, MES, RIM, safety and literature sources — each with its own qualification status.
Nothing. This is the upstream edge.
Effective-dated, version-pinned extracts, each traceable to the controlled record it came from.
EDC, CTMS and the trial master file. Study data under change control, where every correction carries a reason and an audit entry.
LIMS and ELN across discovery, development and QC. Instrument-adjacent, with results that mean nothing without their method and batch.
Submissions, health-authority commitments, product registrations and their status by market. Deadlines here are legal, not aspirational.
Deviations, CAPA, change control and validation records. The system that decides whether anything you build is allowed to be used.
Case intake, coding to MedDRA and expedited reporting, on clocks measured in days.
SOPs, protocols, study reports and labelling — versioned, effective-dated and approved, with superseded versions retained rather than deleted.
Knowing which source systems are GxP-qualified and what that means for yours.
Building against the current version of a document. In a GxP estate the question is always "what was effective on the date of the event", and a system that cannot answer it is not validatable.
ALCOA+ data integrity, audit trails and controlled transformation into the analysis layer.
Read-mostly access paths, change feeds and document streams from the systems of record.
Replayable, resolved, quality-checked records with their lineage back to the source row.
Reads the source’s own change log rather than polling it, so the platform sees every state a record passed through instead of only where it ended up.
Every extract kept as it arrived, immutable and timestamped. The thing you replay from when a downstream definition turns out to have been wrong.
Layout-aware extraction over the unstructured half of the estate: sectioning, tables, signatures, and the page reference every later citation depends on.
Decides that two records are the same real-world thing, with a survivorship rule and a confidence, so downstream joins are a decision rather than an assumption.
Schema, freshness and volume expectations asserted at the boundary, so a bad load fails loudly here rather than quietly two layers later.
Data integrity evidence: attributable, legible, contemporaneous, original, accurate.
Snapshot loads instead of change capture. It looks identical in a demo and it silently loses every intermediate state, which is exactly what an audit later asks you for.
CDISC standards, controlled vocabularies, entitlements and the validated data catalogue.
Replayable, resolved records with lineage from ingestion.
Typed, classified, defined data an agent can be grounded on without inferring meaning.
One agreed definition per term, owned by a named person, so the number an agent quotes means what the business means by it.
The typed entities and relationships the domain actually has, so an agent can traverse "which customers are exposed to this" rather than guess from adjacent text.
Metrics defined once, in one place, with their filters and grain. Removes the class of error where the agent computed something plausible and wrong.
Sensitivity labels and the purpose each classification permits, applied at the field level and inherited by everything downstream.
Where a value came from and what it touched on the way. The layer that makes an answer defensible rather than merely correct.
Computer system validation evidence, versioned prompts and models, and the change control that makes a modification allowable rather than merely deployed.
Making terminology and standards machine-usable rather than documented-only.
Letting the model infer meaning from column names. It will, it will be plausible, and nobody will notice until the number reaches a regulator or a board pack.
Retrieval over literature, protocols, dossiers and the approved claims library with citations.
Typed, classified, defined data from the governance layer.
Ranked, permission-trimmed, citable evidence scoped to the caller and the moment.
Vector and lexical retrieval together, because exact identifiers, codes and clause numbers are the thing semantic search is worst at.
Splits on the document’s own structure and carries effective dates, version and source into every chunk, so a retrieved passage knows when it was true.
Applies the caller’s permissions inside the query rather than filtering results afterwards, so the model never sees what the user may not.
Traverses the knowledge graph for questions that are joins rather than similarity — exposure, genealogy, ownership, causation.
Reorders candidates on relevance and returns the passage identifier behind every sentence, so the answer can be checked rather than trusted.
Citation fidelity strong enough for a regulatory reviewer to follow.
Filtering results after retrieval instead of constraining the query. The model has already seen the rows you removed, and it will use them.
Document drafting, consistency checking, deviation support and case triage under review gates.
Ranked, permission-trimmed, citable evidence from retrieval.
Actions taken or proposed, each with the evidence, the identity and the trace behind it.
Plans, calls tools and holds the loop. Where the step budget, the timeout and the stopping condition are enforced rather than hoped for.
Typed, permissioned tools with declared schemas. An agent’s real capability surface is this list, which is why the list is a security artefact.
Durable task state with checkpoints, so a run that dies mid-way resumes instead of restarting and re-doing side effects.
Approval steps on the actions that need one, carrying enough context for the approver to actually decide rather than rubber-stamp.
Writes back into the systems people already work in, under a service identity with its own audit trail.
Ensuring the agent drafts and proposes; a qualified person decides.
An agent that acts under a service account rather than on behalf of the user. It will eventually do something the requesting user had no right to do, and the log will not show it.
Intended use, risk assessment, IQ/OQ/PQ evidence, change control and periodic review.
Proposed actions and drafted responses from the agent layer.
Permitted, grounded, logged output — or a refusal with a stated reason.
The rules that decide whether an action is permitted at all, evaluated before the action and independently of the model that proposed it.
Injection detection on the way in, and on the way out the checks for leakage, unsupported claims and content the domain forbids.
Verifies each assertion resolves to retrieved evidence, and fails the response rather than shipping the sentence that does not.
Model inventory, intended use, validation evidence and the sign-off that lets a model be used for a purpose. Not optional in a regulated estate.
Immutable record of what was asked, retrieved, decided and done — the artefact a reviewer reads when they do not take your word for it.
Attributable, legible, contemporaneous, original and accurate records of every automated action, retained for the record’s lifetime.
The validation package — generated as you build, never reconstructed afterwards.
A prompt change shipped without change control. In a validated estate that is not a deployment, it is a deviation.
Performance evals, continuous monitoring, drift detection and requalification triggers.
Permitted, grounded, logged output from the guardrail layer.
Measured quality, cost and latency — and the evidence to change any of the three.
Held-out sets and graded runs on every change, so a prompt edit is a measured change rather than a hopeful one.
Blocks a release when quality drops, in CI, on the same evidence for everyone. The difference between a system and a demo.
End-to-end spans across retrieval, model and tool calls, so a bad answer can be opened and read rather than argued about.
Cost per task and per tenant, against throughput and quota. The number that decides whether the pilot can become the rollout.
Watches quality against production traffic rather than the test set, and routes real corrections back into the eval suite.
Defining, in advance, the drift threshold that triggers revalidation.
Evaluating once, before launch. Quality moves with the data, the model and the traffic, and a system with no live measurement has no idea which of the three moved.
Validation scope follows the documented intended use. Broaden what the agent does and you re-open validation.
A model that silently updates invalidates your qualification. Pin versions and treat upgrades as change control.
Every transformation needs an audit trail. Retrofitting one is the most common GxP failure in AI projects.
A qualified person makes the decision. The agent may assemble, draft and check — never release.
Start where GxP does not bite — literature, commercial, medical information — and earn the right to move into validated territory with the evidence you generated on the way.
Filter by stage or by earned autonomy. Selecting a use case jumps the value chain and the architecture to the stage and layer it depends on.
No use cases match that combination.
How a life sciences deployment actually runs.
Establish whether the workflow is GxP-regulated before anything else. It changes the timeline, the evidence burden and the team.
Document intended use and context of use up front. Everything in validation follows from it, and scope creep re-opens it.
Generate validation evidence as a by-product: versioned data, pinned models, logged runs. Retrofitting this is the classic failure.
Run IQ/OQ/PQ against cases quality helped select, and define the drift threshold that would trigger requalification.
Put the system under change control with a periodic review schedule and a named system owner.
8 modules, 80 taught hours, 40 hands-on labs and 8 assessments — every lab provisioned and graded by the SCIKIQ Agentic AI Playground. Open a module to see its labs.
End-to-end agent design, development, deployment and testing, 10 hours each. Reviewed by a Senior SCDAI Engineer against a published rubric.
Build an agent that assembles evidence from a dossier and drafts a health-authority query response with complete traceability — plus the validation evidence package for it.
Build an agent that retrieves comparable deviations and prior CAPAs, structures the evidence and drafts the investigation record for qualified-person review, under change control.
Every lab in this program follows the shape below. This is lab 05 in full — the brief you are given, the environment that is provisioned for you, the code you start from and the assertions that decide whether you passed.
Make ungrounded assertion a build failure rather than an output.
Draft a regulatory document section from a submitted source set. The agent must assert only what is retrievable, and fail the run when it cannot ground a statement. Hedging language in the source must survive into the draft unflattened.
def draft_section(brief, corpus):
"""Draft, then verify. Any sentence without a resolvable citation
fails the run -- it is not silently dropped."""
draft = generate(brief, retrieve(brief, corpus))
unsupported = [s for s in sentences(draft) if not resolves(s, corpus)]
raise NotImplementedError
Every module ends with a timed, randomised assessment delivered through the SCIKIQ Agentic AI Playground. The certificate requires a pass on all of them plus two reviewed capstones.
What each test covers, how long it runs, and how many items are currently in the versioned bank behind it.
| # | Assessment & coverage | Items | Time | In bank |
|---|---|---|---|---|
| 01 | Operating model & GxP scopingDelivery mandateGxP classificationIntended useValue sizing | 25 | 35 min | 4 |
| 02 | Life sciences data landscapeCDISC and eCTDManufacturing dataLiteratureData integrity | 25 | 35 min | 4 |
| 03 | Context engineeringAttributionCertainty and hedgingStructured outputsScope refusal | 25 | 35 min | 4 |
| 04 | Retrieval & groundingLiterature retrievalDossier retrievalClaims matchingRetrieval metrics | 25 | 40 min | 4 |
| 05 | Agent design & autonomyDrafting vs decidingReview gatesConsistency checkingContainment | 25 | 40 min | 4 |
| 06 | Systems integrationMCP designAudit metadataRead-only patternsIdentity | 25 | 35 min | 4 |
| 07 | GxP validation & securityGAMP 5 risk-based validationQualificationChange controlLLM security | 30 | 45 min | 4 |
| 08 | Production & operationsEval gatingContinuous monitoringRequalificationEconomics and handover | 30 | 45 min | 4 |
Real items, drawn from 32 in this program's bank — weighted toward the scenario and diagnosis types, because those are the ones that predict field performance. Instant feedback, nothing saved.
Four sample items — one attempt each, then the reasoning is shown.
Q1Why is the GxP/non-GxP classification the first question on a pharma engagement?
GxP scope drives everything downstream. Discovering it late means re-doing the work with evidence you did not capture.
Q2An eCTD dossier spans thousands of pages across modules. What retrieval property matters most?
When one miss is material, recall dominates. Precision can be recovered by a reviewer; a miss cannot.
Q3Why must scientific claims preserve hedging language?
Certainty calibration is a scientific accuracy requirement. Overstating a finding is a substantive error, not a style issue.
Q4Your literature synthesis omits a contradicting paper. Why is this worse than no synthesis?
Selective evidence presented confidently is actively misleading. Contradiction surfacing is a design requirement here.
The same ladder whichever specialisation you enter through — what changes is the domain you go deep in. Below: how the program is delivered, the skills it moves, the roles it leads to, and the specialisations closest to this one.
The same labs, assessments and capstones, delivered to an enterprise cohort or to individual professionals.
Cohorts of 20 to 2,000+ on your own tenancy, with your data patterns and your cloud. Skill-gap baselining up front, per-team mastery reporting throughout, and capstones scoped against your real backlog so the output is deployable work.
The same labs, assessments and capstones for individual engineers and analysts, run on shared infrastructure with a fixed cohort calendar. You leave with a graded portfolio, not a certificate of attendance.
Find your row and aim one column right. The Playground scores you against this after every module.
| Skill | Beginner | Intermediate | Advanced |
|---|---|---|---|
| Life sciences fluency | Knows the stages. | Maps the chain to gates and owners. | Sizes value and navigates Quality early. |
| GxP validation | Aware of GxP. | Writes intended use and qualification evidence. | Designs validatable AI systems from the start. |
| Scientific grounding | Retrieves papers. | Guarantees attribution and certainty. | Achieves recall on corpora where a miss matters. |
| Context engineering | Writes clear prompts. | Structures retrieval, tools and state deliberately. | Designs context strategy for reliability and cost at scale. |
| Retrieval & grounding | Builds basic vector search. | Tunes chunking, hybrid search and reranking. | Designs graph + vector grounding with measured recall. |
| Agent orchestration | Runs a single tool-calling agent. | Builds supervised multi-step and multi-agent flows. | Designs autonomy boundaries and failure containment. |
| Tool & system integration | Calls a documented API. | Writes an MCP server over a system of record. | Designs a least-privilege tool estate across systems. |
| Evaluation | Eyeballs outputs. | Builds labelled eval sets and regression gates. | Runs online evals with drift and judge calibration. |
| Observability & cost | Reads logs. | Traces runs, tracks tokens and latency. | Owns cost per task and capacity planning in production. |
| Security & guardrails | Adds output filters. | Mitigates the OWASP LLM Top 10 in a build. | Threat-models an agent estate and proves controls. |
| Client delivery | Takes notes in a workshop. | Runs discovery and scopes a thin slice. | Owns the account technically, from scope to handover. |
The SCDAI ladder is the same whichever specialisation you enter through — what changes is the domain you go deep in.
Skill a team, or join a cohort
B2B cohorts run on your tenancy with capstones scoped to your backlog. B2C cohorts run on a fixed calendar.
Stated plainly enough to rule yourself in or out without a sales call: the prerequisites, how the program runs, exactly what the credential is worth, and the questions everyone asks.
Stated plainly so you can rule yourself in or out without a sales call. Nothing here is a formal qualification — it is what the first lab assumes you can already do.
You should already be able to do these
What we assume, and what we teach
What the program asks of your week
Cohort dates and pricing are confirmed on enquiry rather than printed here, because both move with the intake.
The credential is awarded per specialisation, so it names the domain or stack you were assessed in rather than claiming general competence. On this program the badge reads SCDAI — Life Sciences / Pharma.
A certificate that cannot be checked is decoration. Every award resolves to a record showing the specialisation, the award date and the assessments passed.
This is the credential the program awards, shown exactly as it is issued — with the specialisation named, the assessment record attached and a verification link anyone can check without an account.
This is to certify that
Your name
has been assessed and certified as
SCIKIQ Certified Data and AI Engineer
Life Sciences / Pharma
Not “Data and AI Engineer” but the domain or stack you were actually assessed in. A general claim would be a weaker one.
Modules passed, labs graded and both capstones reviewed — so the credential states what was measured rather than that you attended.
The credential ID resolves to a public record showing the specialisation, the award date and the assessments passed.
Add it to your LinkedIn profile in one step. The link pre-fills the certification fields from the credential record, so the entry on your profile matches the record a reader can check.
Add to LinkedIn profile The button is live on your real certificate; here it opens LinkedIn pre-filled with this specialisation so you can see exactly what the profile entry will say.A certificate that cannot be checked is decoration. Every award resolves to a record showing the specialisation, the award date and the assessments passed.
The objections that come up in every conversation about this program, answered without the brochure voice.
Both, and the second is the point. Eight timed assessments and two reviewed capstones stand between you and the credential, so a pass means someone measured the skill rather than recorded your attendance.
Every lab is provisioned, graded and unblocked by the Playground rather than by an instructor. That is what lets a cohort of 2,000 cost the same faculty time as a cohort of 20 — and why you are never waiting on someone to mark your work.
Two retakes are included per assessment, each drawing a fresh item set from the bank, so a retake is a genuinely new paper rather than the same questions again.
For the domain specialisations, no — labs run in provisioned sandboxes. For the four tech-stack programs you will want access to that platform, since deploying into a real subscription is much of the point.
Yes. B2B cohorts run on your own tenancy with your data patterns, a skills baseline before kick-off, per-team mastery reporting, and capstones scoped against your actual backlog so the output is deployable work rather than an exercise.
Take the domain you deploy into. If you move across industries, take a tech-stack program instead and pick up domain context on the engagement. The chooser on the programs page will narrow it.
The trends, platform capabilities and regulatory positions are reviewed each quarter, and every external claim on these pages links to its source so you can check the date yourself.
A graded portfolio: forty machine-graded labs, two reviewed end-to-end agent builds with measured evaluation and cost per task, and a verifiable credential naming your specialisation.
Still deciding?
Tell us the systems you deploy into and we will say plainly whether this specialisation is the right one — or which of the 21 is.